Open in App
  • U.S.
  • Election
  • Newsletter
  • PBS NewsHour

    Here's a list of drugs affected by Biden's latest Medicare pharmaceutical price cuts

    By Associated Press,

    5 hours ago
    https://img.particlenews.com/image.php?url=1iZr8F_0uz44J1R00
    Boxes of the drug NovoLog, made by Novo Nordisk Pharmaceutical, sit on a counter at a pharmacy in Provo, Utah, in 2020. Photo by George Frey/ Reuters

    The Biden administration says Medicare recipients will save about $1.5 billion on out-of-pocket costs for medications to treat diabetes, heart disease, types of arthritis and other ailments under new prices negotiated with drug companies that will take effect in 2026.

    WATCH: Biden and Harris announce deal to cut Medicare prices of popular drugs

    The savings range from 79 percent for Januvia, used to manage diabetes, to 38 percent for Imbruvica, which is used to treat blood cancers. That is the medication’s cost before any discounts or rebates are applied, but not what the price people actually pay when filling their prescriptions.

    A look at the drugs and the negotiated prices.

    Januvia

    Manufacturer: Merck Sharp Dohme

    Conditions: Diabetes

    Negotiated price: $113 for a 30-day supply

    Reduction: 79 percent

    Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill:

    Manufacturer: Novo Norodisk

    Conditions: Diabetes

    Negotiated price: $119 for a 30- day supply

    Reduction: 76 percent

    Farxiga

    Manufacturer: AstraZeneca AB.

    Conditions: Diabetes, heart failure and chronic kidney disease

    Negotiated price: $178.50 for a 30-day supply

    Reduction: 68 percent

    Enbrel

    Manufacturer: Immunex Corp.

    Conditions: Rheumatoid arthritis, psoriasis and psoriatic arthritis

    Negotiated price: $2,355 for a 30-day supply

    Reduction: 67 percent

    Jardiance

    Manufacturer: Boehringer Ingelheim

    Conditions: Diabetes, heart failure and chronic kidney disease

    Negotiated price: $197 for a 30-day supply

    Reduction: 66 percent

    Stelara

    Manufacturer: Janssen Biotech Inc.

    Conditions: Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis

    Negotiated price: $4,695 for a 30-day supply

    Reduction: 66 percent

    Xarelto

    Manufacturer: Janssen Pharms

    Conditions: Prevention and treatment of blood clots. Reduction of risk for patients with coronary or peripheral artery disease

    Negotiated price: $197 for a 30-day supply

    Reduction: 62 percent

    Eliquis

    Manufacturer: Bristol Myers Squibb

    Conditions: Prevention and treatment of blood clots

    Negotiated price: $231 for a 30-day supply

    Reduction: 56 percent

    Entresto

    Manufacturer: Novartis Pharms Corp

    Conditions: Heart failure

    Negotiated price: $295 for a 30-day supply

    Reduction: 53 percent

    Imbruvica

    Manufacturer: Pharmacyclics LLC

    Conditions: Blood cancers

    Negotiated price: $9,319 for a 30-day supply

    Savings: 38 percent

    Expand All
    Comments / 0
    Add a Comment
    YOU MAY ALSO LIKE
    Most Popular newsMost Popular
    US News and World Report12 hours ago

    Comments / 0